What are the key takeaways from this The Life Science Rundown episode?

Key insights include: **Cross-Functional Integration:** Embed regulatory, marketing, clinical, and R&D stakeholders into the product development process from day one rather than treating compliance as a final gate. When these disciplines coexist early, they calibrate each other's risk tolerance, accelerating both innovation and submission readiness without sacrificing scientific rigor or safety standards.; **Project Room Cadence:** Structure cross-functional teams around a physical or virtual project room with daily stand-up meetings where each function reports KPI status — on track or off track — against a visible timeline. The project manager acts as an independent Maestro, not embedded in any single function, to maintain neutrality and accountability across all stakeholders.; **Leading Indicator KPIs:** Avoid single long-horizon KPIs like "complete verification and validation." Instead, map milestone-based leading indicators — feasibility test results, dry-run clinical study completion — that signal trajectory toward the final goal. Without these intermediate markers, risk goes unmanaged and teams face avoidable late-stage surprises that compress timelines and inflate costs.

What did Marwan Fathallah discuss on The Life Science Rundown?

Marwan Fathallah, CEO of DIA Global with 30 years in life sciences, outlines the leadership framework required to move products from concept to commercialization, covering cross-functional team structure, daily management cadence, KPI design, conflict resolution, and the cultural balance between innovation and regulatory rigor. Key topics include: **Cross-Functional Integration:** Embed regulatory, marketing, clinical, and R&D stakeholders into the product development process from day one rather than treating compliance as a final gate. When these disciplines coexist early, they calibrate each other's risk tolerance, accelerating both innovation and submission readiness without sacrificing scientific rigor or safety standards.; **Project Room Cadence:** Structure cross-functional teams around a physical or virtual project room with daily stand-up meetings where each function reports KPI status — on track or off track — against a visible timeline. The project manager acts as an independent Maestro, not embedded in any single function, to maintain neutrality and accountability across all stakeholders..

How long is this episode of The Life Science Rundown?

This episode is 46 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

The Life Science Rundown

Leading Cross-Functional Teams from Concept to Commercialization with Marwan Fathallah

October 6, 2025

46 min episode · 2 min read

Marwan Fathallah

Episode

46 min

Read time

2 min

Topics

Fundraising & VC, Leadership, Design & UX

AI-Generated Summary

Published Mar 16, 2026

Key Takeaways

✓Cross-Functional Integration: Embed regulatory, marketing, clinical, and R&D stakeholders into the product development process from day one rather than treating compliance as a final gate. When these disciplines coexist early, they calibrate each other's risk tolerance, accelerating both innovation and submission readiness without sacrificing scientific rigor or safety standards.
✓Project Room Cadence: Structure cross-functional teams around a physical or virtual project room with daily stand-up meetings where each function reports KPI status — on track or off track — against a visible timeline. The project manager acts as an independent Maestro, not embedded in any single function, to maintain neutrality and accountability across all stakeholders.
✓Leading Indicator KPIs: Avoid single long-horizon KPIs like "complete verification and validation." Instead, map milestone-based leading indicators — feasibility test results, dry-run clinical study completion — that signal trajectory toward the final goal. Without these intermediate markers, risk goes unmanaged and teams face avoidable late-stage surprises that compress timelines and inflate costs.
✓Conflict Resolution Protocol: Address disruptive team dynamics immediately and privately using observation-based language — "I am seeing" rather than accusatory framing — which prevents debate about intent. If behavior persists, escalate to the function head framed as a check-in rather than a complaint, then surface team dynamics formally in the weekly leadership update with proposed options.
✓Systems Thinking Over Silos: Train team members to understand product development as an interdependent system where delaying a regulatory submission to incorporate stronger clinical data may increase approval probability despite disrupting the business plan. Leaders who have held roles across the full development cycle from concept to post-market are measurably less defensive and more effective at these trade-off decisions.

What It Covers

Marwan Fathallah, CEO of DIA Global with 30 years in life sciences, outlines the leadership framework required to move products from concept to commercialization, covering cross-functional team structure, daily management cadence, KPI design, conflict resolution, and the cultural balance between innovation and regulatory rigor.

Key Questions Answered

•Cross-Functional Integration: Embed regulatory, marketing, clinical, and R&D stakeholders into the product development process from day one rather than treating compliance as a final gate. When these disciplines coexist early, they calibrate each other's risk tolerance, accelerating both innovation and submission readiness without sacrificing scientific rigor or safety standards.
•Project Room Cadence: Structure cross-functional teams around a physical or virtual project room with daily stand-up meetings where each function reports KPI status — on track or off track — against a visible timeline. The project manager acts as an independent Maestro, not embedded in any single function, to maintain neutrality and accountability across all stakeholders.
•Leading Indicator KPIs: Avoid single long-horizon KPIs like "complete verification and validation." Instead, map milestone-based leading indicators — feasibility test results, dry-run clinical study completion — that signal trajectory toward the final goal. Without these intermediate markers, risk goes unmanaged and teams face avoidable late-stage surprises that compress timelines and inflate costs.
•Conflict Resolution Protocol: Address disruptive team dynamics immediately and privately using observation-based language — "I am seeing" rather than accusatory framing — which prevents debate about intent. If behavior persists, escalate to the function head framed as a check-in rather than a complaint, then surface team dynamics formally in the weekly leadership update with proposed options.
•Systems Thinking Over Silos: Train team members to understand product development as an interdependent system where delaying a regulatory submission to incorporate stronger clinical data may increase approval probability despite disrupting the business plan. Leaders who have held roles across the full development cycle from concept to post-market are measurably less defensive and more effective at these trade-off decisions.

Notable Moment

Fathallah argues that when teams lack transparent communication, individuals fill the information vacuum by constructing their own internal narratives — and those self-generated stories are almost always worse than the actual situation, making transparency a risk-mitigation tool as much as a cultural value.

Know someone who'd find this useful?

Episode Transcript

Hello, everyone. Welcome to the life science rundown. This is Nicholas Catman with the FDA group. Before we jump into our discussion for today, just a little bit about the FDA group. We help life science companies in the areas of quality assurance, regulatory affairs, clinical operations, commissioning, qualification, and validation, as well as pharmacovigilance. We offer three different engagement models, which are consulting, staff augmentation, and full time employer recruitment. So if you find yourself in need, just head over to the fdagroup.com to check us out and get in touch. So today, I am speaking with Marwan Fatala. How are you, Marwan? Doing good. How are you, Nick? I'm doing excellent. Thanks for joining. Sounds good. Okay. So, so before we jump in for the topic for today, would you kindly introduce yourself? Be happy to. Well, first of all, Nick, thanks for having me. And, for the audience, it's really a pleasure to to connect with you. A little bit of my background. So I've been in the industry for, close to thirty years. I've been very fortunate, to have run a number of functions and and, broader responsibilities and then, executive responsibilities in the life science, sector. So all the way from drug development, to, medical devices, to diagnostics, from running research and development, to operation, to, regulatory clinical scientific affairs, and then, most recently, the chief operating officer in, in a very large diagnostics company and then, obviously, here at, DIA Global as the, CEO. K. Excellent. Thank you for that. So what are we talking about today? Well, I love to share with you a really important topic that I have, learned to appreciate over many, many years, that will, drive a successful outcome in the product development cycle. And that's really about, leadership skills. The leadership skills that are the most critical in each stage of the drug and the development, the drug and device, life cycle. All the way from innovation to patient delivery, and how as, an executive, you can ensure the alignment between these critical stakeholders to deliver a quality product to the customers and, frankly, to the patients, which is what we all serve. So I'm really looking forward to discussing that and touching on the r and d, regulatory, commercial, intersect. So that way we can make sure the patient priorities are well served. Yeah. Excellent. Well, there as we were talking about before we hit record, there's a lot to cover there. So we'll see how deep into this we can get. Sounds good. Probably starting at the, you know, the highest of levels. You know, the word culture, is a, you know, constant theme throughout, leadership and and management and something that I think our industry as well as other industries have been covering in in detail over the past several decades. So why don't we start with what is this type of culture where, you're you're trying to ensure that there's innovation, scientific rigor, and …

Get the full transcript (6,344 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all The Life Science Rundown transcripts →